Published on ADDitudeMag.com

No Cancer Risk with ADHD Meds

Contrary to a previous concerns, new research shows ADHD medications don't increase genetic damage and cancer risk


A new study from Duke University Medical Center and the National Institutes of Health found that two popular medications for treating attention-deficit hyperactivity disorder (ADHD) -- methylphenidate (Ritalin LA and Concerta) and amphetamine (Adderall and Adderall XR) -- do not lead to an increased risk for developing cancer.

The study counters a previous one that reported an increase in genetic damage in children taking methylphenidate. The genetic damage is associated with an increased risk of cancer.

The new study used a larger sample of children, and did not find increased genetic abnormalities.

The study was published in the November online issue of the Journal of the American Academy of Child & Adolescent Psychiatry.

Read more about the study.


Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our
Terms of Service (http://www.additudemag.com/adhd/terms.html) and
Privacy Policy (http://www.additudemag.com/adhd/privacy.html).
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only.
See additional information at http://www.additudemag.com/adhd/disclaimer.html
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018

Adult ADHD | Parenting ADHD Children | ADHD Treatment | School & Learning Disabilities | About ADHD | ADHD Resources | ADHD Community
Source: No Cancer Risk with ADHD Meds